NCT07459270 Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use
| NCT ID | NCT07459270 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Elazığ Mental Health and Diseases Hospital |
| Condition | Methamphetamine Induced Psychosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2026-09-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2026-03-16 with a primary completion date of 2026-09-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective cohort study aims to investigate factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU). Participants hospitalized at Elazığ Mental Health and Diseases Hospital who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MP will be included. Participants will be divided into two groups based on the presence or absence of LCU. Psychiatric symptoms and clinical characteristics will be assessed weekly during an eight-week inpatient follow-up period using standardized psychometric instruments. The study aims to determine whether LCU influences the course and severity of psychiatric symptoms in MP and to identify environmental, individual, and familial factors associated with symptom progression.
Eligibility Criteria
1. For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group: \*Inclusion Criteria: • Diagnosis of MP according to DSM-5-TR * Diagnosis of Cannabis Use Disorder according to DSM-5-TR * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group: \*Exclusion Criteria: • Hypertension • Diabetes mellitus • Chronic kidney disease • Rheumatoid arthritis • Systemic lupus erythematosus • Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MP * Alcohol use disorder 2. For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group: \*Inclusion Criteria: • Diagnosis of MP according to DSM-5-TR • Medication-free for at least one month prior to admission • Age ≥ 18 years and \<65 years • Provided informed consent For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group: \*Exclusion Criteria: • Hypertension • Diabetes mellitus • Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MP * Alcohol use disorder
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07459270 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 65 Years, studying Methamphetamine Induced Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07459270 currently recruiting?
Yes, NCT07459270 is actively recruiting participants. Contact the research team at mhorum@hotmail.com for enrollment information.
Where is the NCT07459270 trial being conducted?
This trial is being conducted at Elâzığ, Turkey (Türkiye), Elâzığ, Turkey (Türkiye).
Who is sponsoring the NCT07459270 clinical trial?
NCT07459270 is sponsored by Elazığ Mental Health and Diseases Hospital. The trial plans to enroll 90 participants.